Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
ABBV · NYSE · Healthcare
Fundamental quality
60
out of 100
Abbvie Inc. earns a fundamental-quality score of 60 out of 100, profiling it as a company of reasonable quality. Its score rests mainly on its financial strength (net debt 3.31× EBITDA). Its weakest area is its growth (revenue +6.4%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
AbbVie is a large U.S. pharmaceutical company. For years it relied on a single blockbuster drug (Humira); today its challenge is to grow with its new generation of medicines, especially in immunology and aesthetics.
EPS growth: 4.9% · Revenue growth: 6.4%
Net margin: 9.8% · ROIC: 23.3%
Net debt/EBITDA: 3.31x · FCF: 28.3%
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 45,804 | 4,616 | 16,790 | 77,573 |
| 2021 | 56,197 | 11,542 | 21,990 | 66,924 |
| 2022 | 58,054 | 11,836 | 24,248 | 54,069 |
| 2023 | 54,318 | 4,863 | 22,062 | 46,571 |
| 2024 | 56,334 | 4,278 | 17,832 | 61,620 |
| 2025 | 61,160 | 4,226 | 17,816 | 61,773 |
Between 2020 and 2025, revenue went from $45,804M to $61,160M (+34%) and net income went from $4,616M to $4,226M (-8%). Meanwhile, its margins have narrowed (from 10% to 7%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$6.65
per share, yearly
65.4% of free cash flow
Payout
54 straight years raising it
Growth
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Abbvie Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Abbvie Inc. a good company to invest in?
In terms of business quality, Abbvie Inc. scores 60 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Abbvie Inc. a profitable company?
Abbvie Inc. is profitable, with a net margin of 9.8%, though a thin one.
Does Abbvie Inc. have a lot of debt?
Yes, its leverage is high: net debt is 3.31 times its EBITDA.
Is Abbvie Inc. growing?
Its revenue has grown 6.4% annualized in recent years and its earnings per share 4.9%.
Does Abbvie Inc. generate cash?
Yes. It converts about 28.3% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Edwards Lifesciences (EW) · Molina Healthcare (MOH) · Medline (MDLN) · Tenet Healthcare (THC) · Universal Health Services (UHS) · Teva Pharmaceutical Industries (TEVA) · see more →
The best Healthcare stocks by our model →
Who's behind the methodology and model · how the score is computed
Data: see Abbvie Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.